Regulation

2 articles

Pharmaceutical executives in a tense meeting with an FDA official, discussing the pause of a new drug approval voucher program.

Drug companies ask FDA commissioner to pause new voucher program

Just months after its announcement, the FDA's Commissioner’s National Priority Voucher Program (CNPV), designed to slash drug approval times to as little as one month, is already facing calls from maj

Marcus Cole·June 5, 2026

AI leaders from major tech companies collaborating on synthetic biology research, highlighting the need for regulation and biosecurity measures.

Life & Biology

AI Leaders Urge Stricter Synthetic Biology Regulation

Leaders from OpenAI, Microsoft, and Google DeepMind have publicly urged governments to enact stricter regulations for synthetic biology.

David Grossman·June 5, 2026